Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KN026 and HB1801 Plus Chemotherapy vs Trastuzumab and Pertuzumab Plus Chemotherapy as Adjuvant Therapy in Resectable HER2-positive Breast Cancer
NCT07441460Phase 3Recruiting
- Sponsor
- Shanghai Jinmante Biotechnology Co., Ltd.
- Start
- Mar 2026
- Primary completion
- Aug 2034
- Modality
- Small Molecules, Nanoparticles, Bispecific Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of anbenitamab, albumin-bound docetaxel in breast cancer, sponsored by Shanghai Jinmante Biotechnology Co., Ltd.. Started Mar 2026; status: recruiting.
02
Drugs
anbenitamabalbumin-bound docetaxel
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT07441460.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07441460.